Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Clay Siegall Biography and Net Worth

Director of Ultragenyx Pharmaceutical

Dr. Siegall currently serves as President, Chief Executive Officer and Chairman of the Board of Seattle Genetics, Inc., a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Dr. Siegall cofounded Seattle Genetics in 1998. Prior to Seattle Genetics, Dr. Siegall worked for the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. In addition to Seattle Genetics, Dr. Siegall serves as a director of Alder BioPharmaceuticals, Inc. and Mirna Therapeutics, Inc., both privately-held biotechnology companies. Dr. Siegall received a B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University.

What is Clay B. Siegall's net worth?: The estimated net worth of Clay B. Siegall is at least $13.54 million as of October 2nd, 2023. Siegall owns 319,636 shares of Ultragenyx Pharmaceutical stock worth more than $13,542,977 as of April 19th. This net worth estimate does not reflect any other investments that Siegall may own. Learn More about Clay B. Siegall's net worth.
How do I contact Clay B. Siegall?: The corporate mailing address for Siegall and other Ultragenyx Pharmaceutical executives is 60 Leveroni Court, Novato CA, 94949. Ultragenyx Pharmaceutical can also be reached via phone at (415) 483-8800 and via email at [email protected]. Learn More on Clay B. Siegall's contact information.
Has Clay B. Siegall been buying or selling shares of Ultragenyx Pharmaceutical?: Clay B. Siegall has not been actively trading shares of Ultragenyx Pharmaceutical during the past quarter. Most recently, Clay B. Siegall sold 11,346 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $85.01, for a transaction totalling $964,523.46. Following the completion of the sale, the director now directly owns 18,204 shares of the company's stock, valued at $1,547,522.04. Learn More on Clay B. Siegall's trading history.
Who are Ultragenyx Pharmaceutical's active insiders?: Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Mardi Dier (CFO), Erik Harris (EVP), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?: During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 137,745 shares worth more than $5,325,628.52. The most recent insider tranaction occured on April, 18th when EVP Eric Crombez sold 142 shares worth more than $6,262.20. Insiders at Ultragenyx Pharmaceutical own 6.8% of the company. Learn More about insider trades at Ultragenyx Pharmaceutical.
Information on this page was last updated on 4/18/2024.

Clay B. Siegall Insider Trading History at Ultragenyx Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2020	Sell	11,346	$85.01	$964,523.46	18,204
8/7/2020	Sell	23,404	$85.55	$2,002,212.20	18,204

Clay B. Siegall Buying and Selling Activity at Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Company Overview

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Today's Range

Now: $42.37

$41.07

$43.92

50 Day Range

MA: $48.01

$42.31

$53.69

2 Week Range

Now: $42.37

$31.52

$54.98

Volume

675,380 shs

Average Volume

764,819 shs

Market Capitalization

$3.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65